levothyroxine teva 25 micrograms tablets
teva pharma b.v. - levothyroxine sodium - tablet - 25 microgram(s) - thyroid hormones; levothyroxine sodium
levothyroxine liquid
deseret biologicals, inc. - levothyroxine (unii: q51bo43mg4) (levothyroxine - unii:q51bo43mg4) - levothyroxine 16 [hp_x] in 1 ml - for the temporary relief of symptoms such as backache, constipation, and vomiting.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for the temporary relief of symptoms such as backache, constipation, and vomiting.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.
levothyroxine 50 micrograms per 5 ml oral solution
mercury pharmaceuticals ltd - levothyroxine sodium - infus/pdr/oral soln - 50 micrograms/5ml - thyroid hormones; levothyroxine sodium
levothyroxine 100 micrograms per 5 ml oral solution
mercury pharmaceuticals ltd - levothyroxine sodium - oral solution - 100 micrograms/5ml - thyroid hormones; levothyroxine sodium
levothyroxine 25 micrograms/5ml oral solution
wockhardt uk limited - levothyroxine sodium - oral solution - 25 micrograms/5ml - thyroid hormones; levothyroxine sodium
levothyroxine 50 micrograms/5ml oral solution
wockhardt uk limited - levothyroxine sodium - oral solution - 50 micrograms/5ml - thyroid hormones; levothyroxine sodium
levothyroxine 100 micrograms/5ml oral solution
wockhardt uk limited - levothyroxine sodium - oral solution - 100 micrograms/5ml - thyroid hormones; levothyroxine sodium
imatinib teva
teva b.v. - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - antineoplastic agents, protein kinase inhibitors - imatinib teva is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr‑abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment.adult and paediatric patients with ph+ cml in chronic phase after failure of interferon‑alpha therapy, or in accelerated phase or blast crisis.adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy.adult patients with relapsed or refractory ph+ all as monotherapy.adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements.adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement.the effect of imatinib on the outcome of bone marrow transplantation has not been determined.imatinib teva is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist).the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatment.the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery.in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5.1). except in newly diagnosed chronic phase cml, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.
levothyroxine sodium tablet
pd-rx pharmaceuticals, inc. - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 88 ug
levothyroxine sodium tablet
pd-rx pharmaceuticals, inc. - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 150 ug